News Feed Opinion Blog Posts Career Updates Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
August, 2025
August 2025
M T W T F S S
 123
45678910
11121314151617
18192021222324
25262728293031
Heidi Ko: How molecular classification impacts targeted therapy options
Photo taken from Heidi Ko/LinkedIn
Sep 8, 2024, 14:49

Heidi Ko: How molecular classification impacts targeted therapy options

Heidi Ko, shared a post on LinkedIn:

“Uterine cancer is the most common gynecologic cancer in the U.S., with increasing incidence and mortality rate. This Molecular Tumor Board case presented is about a 56-year-old female patient with uterine cancer and an underlying POLE V411L alteration. Join us as we discuss molecular subgroups in uterine cancer and how molecular classification impacts targeted therapy options.”

Read further.
Source: Heidi Ko/LinkedIn

cancer Gynecologic Cancer Heidi Ko Molecular Tumor Board OncoDaily Oncology uterine cancer
Special Coverage
Voices
Aug 20, 2025, 16:32
Vinayak Venkataraman: Honored to Join the Jimmy Fund Radio-Telethon With My Patient Jen
Voices
Aug 20, 2025, 16:15
Sanam Loghavi: Never a Dull Day at MD Anderson Cancer Center
Voices
Aug 20, 2025, 15:57
Nico Gagelmann: Registration Is Open for the 10th Congress on COSTEM
Voices
Aug 20, 2025, 15:57
Nieves Martinez Lago: NETs/NENs Gain Dedicated Category at ASCO GI26
Science
Aug 20, 2025, 15:55
ASCO25 Liquid Biopsy Highlights - International Society of Liquid Biopsy
Voices
Aug 20, 2025, 15:54
Chrystal Paulos Has Been Awarded V Foundation All-Star Grant - Winship Cancer Institute of Emory University
Voices
Aug 20, 2025, 15:52
Kirsten Efremov: Strengthening Patient Engagement in the Adolescent and Young Adult Cancer Community
Insight
Aug 20, 2025, 15:42
Joshua Palmer: Pre-Operative Versus Post-Operative Fractionated Stereotactic Radiotherapy
Immune Oncology
Aug 20, 2025, 15:42
New IO Paper Alert: Neutrophil-to-Lymphocyte Ratio as a Predictive Biomarker for First-Line Immunotherapy Outcomes in HCC.
Voices
Aug 20, 2025, 15:41
Rob Winn: The NIH's 15% Indirect Cost Cap - A Misunderstanding of Research Reality
Opinion
Aug 20, 2025, 15:36
Elisabeth Potter: The Impact of Rising Insurance Costs on Breast Cancer Treatment Choices
Voices
Aug 20, 2025, 15:32
Minhua Chu: BNT327 (Pumitamig) Shows Promising Efficacy in ES-SCLC in Phase II Trial